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Background: Completed human papillomavirus (HPV) vaccination by age 16 years among women in
Switzerland ranges from 17 to 75% across 26 cantons. The consequences of regional heterogeneity in vac-
cination coverage on transmission and prevalence of HPV-16 are unclear.
Methods: We developed a deterministic, population-based model that describes HPV-16 transmission
among young adults within and between the 26 cantons of Switzerland. We parameterized the model
using sexual behavior data from Switzerland and data from the Swiss National Vaccination Coverage
Survey. First, we investigated the general consequences of heterogeneity in vaccination uptake between
two sub-populations. We then compared the predicted prevalence of HPV-16 resulting from heteroge-
neous HPV vaccination uptake in all of Switzerland with homogeneous vaccination at an uptake that is
identical to the national average (52%).
Results: In our baseline scenario, HPV-16 prevalence in women is 3.34% when vaccination is introduced
and begins to diverge across cantons, ranging from 0.19 to 1.20% after 15 years of vaccination. After the
same time period, overall prevalence of HPV-16 in Switzerland is only marginally higher (0.63%) with
heterogeneous vaccination uptake than with homogeneous uptake (0.59%). Assuming inter-cantonal sex-
ual mixing, cantons with low vaccination uptake benefit from a reduction in prevalence at the expense of
cantons with high vaccination uptake.
Conclusions: Regional variations in uptake diminish the overall effect of vaccination on HPV-16 preva-
lence in Switzerland, but the effect size is small. Cantonal efforts towards HPV-prevalence reduction
by increasing vaccination uptake are impaired by cantons with low vaccination uptake. Although the
expected impact on national prevalence would be relatively small, harmonization of cantonal vaccination
programs would reduce inter-cantonal differences in HPV-16 prevalence.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human papillomavirus (HPV) is the most common sexually
transmitted infection (STI) of the reproductive tract [1]. Persistent
infections with HVP types 16 and 18 are responsible for 70% of cer-
vical cancers and precancerous cervical lesions [1]. In Switzerland,
around 250 new cases of cervical cancer and some 5000 cases of
precancer have been diagnosed each year, with cervical cancer
being the fifth most frequent type of cancer among women aged
20 to 49 years [2]. The first vaccine against human papillomavirus(HPV) was licensed in 2006 and is now widely used in many coun-
tries. At the population-level, HPV vaccination has led to a substan-
tial reduction in the prevalence of the targeted oncogenic HPV
types (HPV-16/18) and of anogenital warts [3]. Most vaccination
programs target girls or young women before they become sexu-
ally active. Regional differences in vaccination uptake have
emerged in some countries after implementation of the vaccina-
tion programs [4,5]. These differences are very pronounced in
Switzerland where the proportion of 16 year old girls completing
the three dose vaccination schedule ranges from 17 to 75% in 26
cantons (states) (Fig. 1) [6,7]. The cantonal heterogeneity in vacci-
nation uptake can be partly explained by differences in the way the
vaccine is offered to girls and young women (e.g., school-based
programs, general practitioners or gynecologists). Other factors,
such as cultural differences between the cantons might play a role
Fig. 1. HPV vaccination uptake in 16 year old girls in Switzerland. Data represent the last completed survey period (2011–2013) of the Swiss National Vaccination Coverage
Survey. Data for Geneva and Appenzell Innerrhoden are from 2010 and 2014, respectively. The names of the cantons are provided in the Supplementary Material (Fig. S1).
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nal variation in vaccination uptake on transmission and prevalence
of HPV in Switzerland and other countries are not well understood.
Mathematical models have played an important role in estimat-
ing the expected impact of vaccination on the transmission of HPV
[8–10] and other infections [11]. Investigating the consequences of
spatial heterogeneity in vaccination uptake has received less atten-
tion, with some exceptions. Studies on measles vaccination [12,13]
and canine rabies [14] showed that spatial vaccination heterogene-
ity leads to less effective control of the targeted disease when com-
pared with homogeneous vaccination. The debate about
heterogeneity in HPV vaccination uptake has focused on sex-
specific vaccination [15–17]. For the extreme case where only
one sex is fully vaccinated, although coverage would be 50% of
the total population, the transmission would be completely
blocked as the vaccine-targeted sex would act as a dead-end host.
Assuming a fixed unit price per vaccine dose and without consid-
ering further marginal costs of vaccine distribution, sex-specific
vaccination is often considered to be more beneficial than homoge-
neous (male/female) vaccination in a heterosexual population [15–
17]. In contrast, spatial heterogeneity in vaccination uptake is
expected to have a different impact on transmission compared to
sex-specific heterogeneity, as transmission can continue indepen-
dently in spatial sub-populations with low vaccination uptake.
Spatial variation in HPV vaccination uptake between states in the
United States of America (USA) has been taken into account in a
modeling study that quantified the epidemiological impact and
cost-effectiveness of adopting a new, nonavalent HPV vaccine[18]. This study suggested that expanding vaccination coverage
in states with low coverage would result in the greatest health
impact because of the decreasing marginal returns of herd immu-
nity. This finding is supported by another modeling study from
Canada showing that the effect of unequal vaccination uptake
among school girls by ethnicity on cervical cancer incidence may
be lower than with equal vaccination [19]. The effects of spatial
heterogeneity in vaccination uptake crucially depend on sexual
mixing between different regions, as well as herd immunity
thresholds and other disease-specific characteristics. A better
understanding of how these factors affect the transmission and
prevalence of HPV may help to better interpret the expected or
observed impact of HPV vaccination programs.
The aim of this study was to investigate the impact of heteroge-
neous vaccination uptake and different sexual mixing scenarios on
the prevalence of HPV-16 in Switzerland. We developed a mathe-
matical model of HPV-16 transmission among young heterosexual
adults. We parameterized the model using Swiss sexual behavior
data and calculated the pre-vaccination prevalence and the basic
reproduction number (R0) of HPV-16. First, we investigated the
general consequences of heterogeneous vaccination uptake in a
simple model with two sub-populations. We then simulated the
transmission of HPV-16 within and between the 26 cantons of
Switzerland assuming three different scenarios for inter-cantonal
sexual mixing. We compared the predicted post-vaccination preva-
lence of HPV-16 after the introduction of heterogeneous HPV vac-
cination uptake with a default scenario of homogeneous
vaccination.
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2.1. HPV-16 transmission model
We developed a deterministic, population-based model of HPV
transmission, based on well-established work on modeling STIs
[20–22]. For simplicity, we focused on HPV-16 only as it is the
most common oncogenic type in women worldwide [23] and
responsible for more than 50% of invasive cervical cancers [24].
We implemented the spatial (cantonal) structure into a meta-
population model, and considered the population of 18–24 year
old heterosexual Swiss adults who can be susceptible (S), infected
(I), recovered (R) or vaccinated (V). These compartments are fur-
ther divided into sub-compartments that reflect the individuals’
sex, sub-population/canton and sexual activity level, and can be
described by the following system of ordinary differential equa-
tions (ODEs):
dSskr
dt
¼ ð1 pskveÞlNskr  kskrSskr þxRskr  lSskr ð1Þ
mSskr þmnr
X
u
Ssku; ð2Þ
dIskr
dt
¼ kskrSskr  cIskr  lIskr mIskr þmnr
X
u
Isku; ð3Þ
dRskr
dt
¼ cIskr xRskr  lRskr mRskr þmnr
X
u
Rsku; ð4Þ
dVskr
dt
¼ pskvelNskr  lVskr mVskr þmnr
X
u
Vsku: ð5Þ
Here, the subscripts s; k and r denote sex, sub-population/
canton and sexual activity group, respectively. Susceptible
individuals (S) can become infected at rate kskr (force of infection).
Infected individuals (I) spontaneously clear HPV-16 at rate c to
become temporarily immune. Recovered individuals (R) lose
their immunity at rate x and become susceptible again. All
individuals enter and leave the population at rate l with
Nskr ¼ Sskr þ Iskr þ Rskr þ Vskr being the population size of individuals
that have sex s, reside in sub-population/canton k and belong to
sexual activity group r. psk is the sub-population- or canton-
specific proportion of individuals that are vaccinated upon enter-
ing the population, with ve being the vaccine efficacy. We assumed
that vaccine protection lasts for an individual’s sexual lifetime.
Finally, heterogeneity in sexual activity can occur at the individual
level as well as between activity classes [25]. We assume that indi-
viduals can change their sexual behavior at rate m, i.e., they are
redistributed to either the same or another sexual activity group
proportional to the size of the target group, nr [22,26].
2.2. Data and parameters
2.2.1. Vaccination uptake
We used data from the Swiss National Vaccination Coverage
Survey (SNVCS) to obtain the proportion of women who are vacci-
nated in each canton (Fig. 1, Supplementary Material Table S1). The
SNVCS monitors immunization coverage of children and adoles-
cents and compiles them into three-year bands. For HPV vaccina-
tion, the surveys focus on 16 years old girls only. In this study,
we used data from the last available survey period (2011–2013),
except for the canton of Geneva (GE) and Appenzell Innerrhoden
(AI) where we used data from the years 2010 and 2014, respec-
tively. Two HPV vaccines are currently authorized in Switzerland:
Gardasil (MSD Merck Sharp & Dohme AG, Luzern) which targets
four HPV types (HPV-6/11/16/18), and Cervarix (GlaxoSmithKline
AG, Münchenbuchsee) which targets two HPV types (HPV-16/18).95% of vaccinated women received the quadrivalent vaccine [6].
We used the proportion of fully vaccinated women (completed
three doses) as a model parameter. Although Switzerland adopted
the two-dose HPV vaccination schedule in 2012, we assumed that
this had not been implemented in the cantonal programs at the
time the surveys were done. We did not consider HPV vaccination
in boys and young men, as uptake in Switzerland was negligible
before 2016.
2.2.2. Sexual behavior
We used data from the SIR (Screening, Impfung und Risikofak-
toren) survey [6]. The Swiss Federal Office of Public Health (FOPH)
conducted this survey in 2014 and collected data on the sexual
behavior of 18–24 year old Swiss women (n ¼ 1291). We catego-
rized the study participants into two sexual activity groups and
estimated the sexual partner change rates by assuming that the
distribution of the reported numbers of new heterosexual partners
in the last year can be modeled as a mixture of two Poisson distri-
butions, weighted by the proportion of individuals in each sexual
activity group [27,22]. The survey did not include men, so we
assumed their sexual activity to be the same as for women. Fur-
thermore, we assumed that sexual behavior does not differ
between cantons.
2.2.3. Inter-cantonal mixing
We used mobility data from the Swiss Federal Office for Spatial
Development as a proxy for sexual mixing between different can-
tons. The data set contains average daily commuting data by public
transport and individual vehicles from Monday to Friday in 2010
[28].
2.2.4. Other parameters
We used publicly available data about the number of 18–24
year olds in each canton in 2013 from the website of the Swiss Fed-
eral Statistical Office [29] (Supplementary Material Table S2).
Parameters that describe the transmission and natural-history of
HPV-16 were informed by the literature [30,31] and assumed to
be the same for women and men. All parameter values and their
sources are specified in Table 1.
2.3. Sexual mixing and force of infection
In our model, the force of infection, kskr , depends on assump-
tions about sexual contact preferences between individuals from
different sexual activity groups and sub-populations/cantons. We
devised three different scenarios of increasing complexity to
account for different spatial mixing patterns (Fig. 2):
1. Assortative sexual mixing: Sexual contacts only occur between
individuals from the same sub-population/canton.
2. Proportional sexual mixing: A fraction of sexual contacts occur
between individuals from the same sub-population/canton,
while the remaining contacts are proportionally distributed
across all sub-populations/cantons.
3. Mobility-informed sexual mixing: Swiss mobility data are used as
a proxy for inter-cantonal sexual mixing.
2.3.1. Assortative and proportional sexual mixing
In the first two scenarios, where we assumed fully assortative or
partial proportional mixing between sub-populations/cantons, the
force of infection is given by:
kskr ¼ bcr
X
k0
X
r0
qss0kk0rr0
Is0k0r0
Ns0k0r0
; ð6Þ
Table 1
Summary of parameters for the HPV-16 transmission model. Where applicable, baseline values are shown together with confidence intervals (CI), posterior intervals (PI) or the
range that was considered in the uncertainty analysis.
Parameter Description Value Unit Reference/Comment
Nskr Number of 18–24 year olds of sex s, sub-population/canton k and activity group r See Table S.2 – Swiss FSO
nl Proportion in the low sexual activity group 0.85 (95% CI: 0.83–0.87) – Estimated
nh Proportion in the high sexual activity group 0.15 (95% CI: 0.13–0.17) – Estimated
cl Heterosexual partner change rate in low activity group 0.17 (95% CI: 0.14–0.20) per year Estimated
ch Heterosexual partner change rate in high activity group 2.41 (95% CI: 2.18–2.65) per year Estimated
l Rate at which individuals enter and leave the population 0.14 per year 7-year age band
m Rate at which individuals can change activity groups 1.0 (range: 0.00–1.00) per year [26,22]
r Assortativity index for sexual mixing between activity groups 0.5 (range: 0.00–1.00) – [26,22]
k Assortativity index for sexual mixing between sub-populations/cantons 0.6,0.8,1.0 – Assumption
s Scaling factor for mobility-informed sexual mixing matrix rkk0 0.035 – Calculated
b Transmission probability per partnership 0.8 (95% PI: 0.60–0.99) – [30]
c Rate at which infection is cleared spontaneously 0.55 (95% PI: 0.15–1.16) per year [31]
x Rate at which immunity is lost 0.024 (95% PI: 0.011–0.032) per year [31]
psk Proportion of vaccinated individuals in canton k Fig. 1 – Swiss FOPH
ve Vaccine efficacy against persistent HPV-16 infection 0.94 (95% CI: 0.91–0.96) – [32]
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sexual partner change rate for individuals of sexual activity group r.
The elements of the sexual mixing matrix
qss0kk0rr0 ¼qss0kk0qrr0
kdkk0 þ ð1 kÞ
P
vcvNs0k0vP
u
P
vcvNs0uv
 
ð7Þ
 rdrr0 þ ð1 rÞ cr
0Ns0k0r0P
vcvNs0k0v
 
ð8Þ
describe the conditional probability that an individual of sex s, sub-
population/canton k and sexual activity group r has a sexual contact
with an individual of the opposite sex s0, sub-population/canton k0
and sexual activity group r0. k and r are the sexual mixing coeffi-
cients with respect to sub-population/canton and sexual activity
group, respectively. A value of 1 represent fully assortative mixing
where individuals only have sexual contacts with other individuals
from the same sub-population/canton or sexual activity group. A
value of 0 corresponds to proportional (random) mixing where sex-
ual partners are chosen in proportion to the size of their sub-
population/canton and their sexual activity group. dkk0 and drr0 are
the Kronecker deltas, which are equal to 1 if k ¼ k0 or r ¼ r0 and to
0 otherwise. In the first scenario (assortative sexual mixing), we
set k ¼ 1. In the second scenario (proportional sexual mixing), we
set k to 0.6 (model with two sub-populations) and 0.8 (cantonal
model). Throughout all simulations, we set r ¼ 0:5, which corre-
sponds to partially assortative mixing with respect to sexual activ-
ity [26,22].
2.3.2. Mobility-informed sexual mixing
We used mobility data as a proxy for inter-cantonal sexual mix-
ing. We assumed that the heterosexual partner preference across
cantons is proportional to the corresponding commuting patterns.
The symmetrical matrix Pmob provides absolute numbers of
commuters between cantons without specifying the commuters’
canton of residence. We converted Pmob into an asymmetrical
inter-cantonal mixing matrix rkk0 that provides the conditional
probabilities that a sexual contact from an individual from canton
k occurs with someone from canton k0. To this end, we first rescaled
Pmob by a scaling factor s and weighted all columns with the inverse
of the cantonal population size:
rkk0 ¼ s
Pmob
Nk
: ð9Þ
We then replaced the diagonal entries of rkk0 with the sum of all
entries that are outside canton k:rkk # 1
X
i–k
rki: ð10Þ
The force of infection for the mobility-informed sexual mixing sce-
nario is given by Eq. (6) with qss0kk0rr0 being replaced by rkk0qss0rr0 . We
chose the scaling factor s such that the weighted proportion of
intra-cantonal heterosexual contacts across all cantons is 80% (Sup-
plementary Material Fig. S2), i.e., is the same as in the proportional
sexual mixing scenario:
X
k
rkk
NkP
kNk
¼ 0:8: ð11Þ2.4. Model simulations
We simulated the different model scenarios by numerically
integrating the ODEs until the system approached the endemic
pre-vaccination equilibrium (psk ¼ 0). We then initiated the HPV
vaccination program by setting psk > 0, and ran the model for a fur-
ther number of years. The ODEs were solved in the R software envi-
ronment for statistical computing [33] using the function ode from
the package deSolve. We calculated the basic reproduction number
(R0) using the next-generation matrix method as described by
Diekmann et al. [34,35] (Supplementary Material Section 1). This
allowed us to compute the vaccination threshold VC ¼ 11=R0ve . Model
simulations were performed on UBELIX (http://www.id.unibe.ch/
hpc), the high performance computing (HPC) cluster at the
University of Bern. All code files can be downloaded from GitHub
(https://github.com/mauraner/HPV-regional-vaccine-heterogeneity-
model).2.4.1. Uncertainty analysis
In addition to our baseline scenario, we investigated the robust-
ness of our results taking into account the uncertainty around crit-
ical parameters. We used a set of 1,000 different parameter
combinations, based on the intervals provided in Table 1. For the
sexual behavior parameters (nl;nh; cl; ch), we randomly drew from
a normal distribution with the corresponding 95% confidence
interval (CI). HPV-related parameters (b; c;x;ve) were chosen uni-
formly within the corresponding 95% posterior intervals (PI) or CI.
Finally, we randomly selected the parameters m and r from a uni-
form distribution between 0 and 1. We conducted the uncertainty
analysis with the sub-set of 858 parameter combinations that
resulted in a non-zero prevalence (> 0:01%).
Fig. 2. Chord diagrams of inter-cantonal sexual mixing. The diagrams show the
number of sexual contacts between individuals from different cantons. For the
scenarios where sexual mixing between cantons occurs (proportional and mobility-
informed sexual mixing), we excluded the sexual contacts between individuals that
reside in the same canton for better visibility. Cantons with a French-, German- or
Italian-speaking majority are indicated in blue, beige and red, respectively.
Acronyms for canton names are explained in the Supplementary Material Table S1.
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3.1. HPV-16 dynamics
Using the parameters from Table 1, the transmission model
provides a realistic description of the HPV-16 dynamics in
Switzerland. The baseline parameters result in a model-based
estimate of the pre-vaccination prevalence of HPV-16 of 3.34%
among 18–24 year olds (median: 3.58%, interquartile range,
IQR: 1.54–7.50%, based on uncertainty analysis). While this is
somewhat lower than the expected and observed HPV-16 preva-
lence in Britain (Supplementary Material Section 2, Table S3), it
is in the range typically observed among women in other
European countries [23]. The functional relationship between
vaccination coverage and the reduction in HPV-16 prevalence 2
to 4 years post-vaccination is in good agreement with the find-
ings of a systematic review (Supplementary Material Section 3,
Fig. S3) [3]. The basic reproduction number, R0, of HPV-16 in
our model is 1.29 (median: 1.42, IQR: 1.08–1.96). This corre-
sponds to a vaccination threshold of 23.5% (median: 34.4%,
IQR: 14.2%-53.8%) in the general population. If vaccination tar-
gets only one sex, the threshold increases to 41.7% (median:
57.6%, IQR: 26.5–80.5%).3.2. Vaccination in two sub-populations
To better understand the effects of spatially heterogeneous
vaccination uptake on infection transmission, we focused on a
simplified model with two sub-populations of the same size.
We calculated the expected HPV-16 prevalence after 15 years of
vaccinating the two sub-populations at different coverage rates
(Fig. 3). In the first scenario, we assumed fully assortative sexual
mixing between the two sub-populations, i.e., sexual contacts
only occur between individuals from the same sub-population
(Fig. 3a). The concave relation between vaccination coverage in
the two sub-populations and the expected prevalence of HPV-
16 overall indicates that homogeneous vaccination uptake typi-
cally has the largest effect on reducing prevalence. For example,
a vaccination coverage of 25% in both sub-populations results
in a lower prevalence than vaccinating either of them at 50%.
In the second scenario, we assumed a certain level of propor-
tional mixing where 20% of sexual contacts are made with indi-
viduals from the other sub-population (Fig. 3b). Sexual mixing
between the two sub-populations diminishes the negative effect
of heterogeneous vaccination uptake, but homogeneous vaccina-
tion still results in the lowest prevalence of HPV-16. Fig. 3c
shows the difference in the expected HPV-16 prevalence between
the first (no sexual mixing between the sub-populations) and
second (sexual mixing between the sub-populations) scenario.
The higher the difference, the stronger the effect of sexual mixing
is in reducing the negative consequences of heterogeneous vacci-
nation uptake. In contrast to this short-term scenario (15 years),
the effect of sexual mixing can change slightly after extreme long
time periods (Supplementary Material Fig. S4). Then, sexual mix-
ing can slightly increase the negative consequences of heteroge-
neous uptake when coverage is below the vaccination threshold
in both populations. However, we do not consider this scenario
relevant for HPV. In summary, these results illustrate that, in
the short-term, spatially heterogeneous vaccination uptake
diminishes the effect of vaccination on reducing HPV-16 preva-
lence, but that sexual mixing between sub-populations can limit
these undesired consequences by ‘homogenizing’ the overall
population.
Fig. 3. Heterogeneous vaccination uptake and HPV-16 prevalence. The graphs show
the expected prevalence of HPV-16 after 15 years of vaccinating the two sub-
populations at different coverage rates. (a) HPV-16 prevalence when there is no
sexual mixing between the two populations. (b) HPV-16 prevalence when 20% of
sexual contacts are made between the two populations (ek ¼ 0:6). (c) Difference in
HPV-16 prevalence between scenario a and b.
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We extended our analysis of heterogeneous vaccination uptake
by simulating the transmission of HPV-16 within and between the
26 cantons of Switzerland. The observed dynamics generalize some
of the insights from the simplified model with two sub-
populations. After vaccination is introduced, HPV-16 prevalence
begins to diverge across cantons (Fig. 4). After 15 years of vaccina-tion, the range of expected HPV-16 prevalences depends on the
assumed scenario for sexual mixing between cantons (see Meth-
ods). Assuming baseline parameters and fully assortative mixing,
the highest and lowest prevalence are 2.20% (ZG, 17% vaccination
coverage) and 0.17% (VS, 75% vaccination coverage), respectively
(Fig. 4a). The range of cantonal HPV-16 prevalence narrows if sex-
ual mixing between cantons is taken into account. The cantonal
prevalence ranges from 1.38% to 0.30% for proportional mixing
(Fig. 4b), and from 1.20% to 0.20% for mobility-informed mixing
(Fig. 4c). Thus, sexual mixing between cantons ‘homogenizes’ the
infection dynamics and the effect of vaccination on reducing
prevalence.
This homogenizing effect is also reflected in the overall preva-
lence of HPV-16 in Switzerland. The national prevalence of HPV-
16 is slightly higher under heterogeneous vaccination uptake com-
pared with homogeneous uptake (Fig. 4). This difference becomes
smaller in the two scenarios that assume sexual mixing between
the two cantons (Fig. 4b and c). In the most realistic scenario
(mobility-informed mixing), the national prevalence of HPV-16 is
expected to drop to 0.55% after 15 years of heterogeneous vaccina-
tion uptake, while homogeneous vaccination uptake would drop
the prevalence to 0.49%. Additional analyses illustrate that the
result of heterogeneous vaccination uptake, yielding a slightly
higher HPV-16 prevalence compared with homogeneous uptake,
is robust with respect to parameter uncertainty (Fig. 4, right-
hand panels), and different assumptions about sexual mixing, sex-
ual activity, cantonal population sizes and the overall vaccination
uptake (Supplementary Material Table S4).
Inter-cantonal sexual mixing helps to reduce the prevalence of
HPV-16 in cantons with low vaccination coverage at the expense of
cantons with high vaccination coverage. At the national level,
increasing sexual mixing between cantons always results in a
lower HPV-16 prevalence (Fig. 5, dashed red lines), while the effect
of sexual mixing at the cantonal level is more nuanced. The num-
ber of cantons that achieve a specific reduction in prevalence –
expressed as relative risk (RR) reduction – can either decrease or
increase with varying degrees of sexual mixing (Fig. 5). For exam-
ple, high levels of sexual mixing between cantons (low k) increase
the number of cantons that achieve a 50% reduction in prevalence
after 15 years of vaccination (Fig. 5a). In contrast, low levels of sex-
ual mixing between cantons (high k) are required to increase the
number of cantons that achieve a RR reduction of 90%. In the long-
term (50 years of vaccination), the number of cantons that reach a
RR reduction of 99% is lowest for low- but realistic- levels of sexual
mixing between cantons (k ¼ 0:80 0:95) (Fig. 5b). These levels
of sexual mixing prevent the elimination of HPV-16 in high-
coverage cantons, but they are too low for low-coverage cantons
to sufficiently benefit from the herd immunity of high-coverage
cantons.4. Discussion
Uptake of HPV vaccination in 16 year old girls in Switzerland
shows pronounced differences between different cantons ranging
from 17 to 75%. We used a dynamic transmission model to study
the expected consequences of this spatial heterogeneity in vaccina-
tion uptake on the transmission and prevalence of HPV-16 in
Switzerland. Using a simple model with two sub-populations, we
found that heterogeneous vaccination uptake can diminish the
effect of vaccination on reducing HPV-16 prevalence in the overall
population. This effect is strongest when vaccination is very
heterogeneous, i.e., when uptake is very high in one sub-
population and very low in the other sub-population. These results
were corroborated with an extended model simulating the trans-
Fig. 4. Cantonal and national prevalence of HPV-16 after vaccine introduction. (a) Fully assortative mixing (no sexual mixing between cantons). (b) Proportional mixing (20%
of sexual contacts are proportionally distributed over all of Switzerland). (c) Mobility-informed mixing. Left-hand panels show the results using the baseline parameter
values. Grey lines represent cantonal HPV-16 prevalence under heterogeneous vaccination and the thick black and red lines correspond to the national prevalence for
heterogeneous and homogeneous vaccination uptake, respectively. Right-hand panels show the difference in the national prevalence between the heterogeneous and
homogeneous vaccination uptake scenarios for all parameter combinations from the uncertainty analysis. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
7318 M. Riesen et al. / Vaccine 35 (2017) 7312–7321mission of HPV-16 within and between the 26 cantons of
Switzerland. Homogeneous vaccination uptake would generate a
lower national HPV-16 prevalence compared to heterogeneous
vaccination uptake, but the overall differences in prevalence arevery small. We found that inter-cantonal sexual mixing ‘homoge-
nizes’ the infection dynamics, limits the undesired consequences
of heterogeneous vaccination uptake, and reduces the inter-
cantonal differences in HPV-16 prevalence.
Fig. 5. Relationship between inter-cantonal sexual mixing and HPV-16 prevalence.
The graphs show the number of cantons that achieve a specific relative risk (RR)
reduction after vaccination in the shortterm (15 years, a) and longterm (50 years,
b). The dashed red lines correspond to the national prevalence which is lowest if
sexual mixing is highest, i.e., completely proportional (k ¼ 0), between cantons.
For all simulations, we used the proportional sexual mixing scenario. (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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eterizing a dynamic transmission model while exhibiting large
variation in HPV-16 vaccine deployment. Using Swiss sexual
behavior data, the model provided a realistic description of HPV-
16 transmission in Switzerland, and allowed us to investigate the
expected effect of HPV vaccination. Our finding that homogeneous
vaccination uptake between cantons would help reduce HPV-16
prevalence in Switzerland does not change qualitatively when
the number of cantons or parameter values are varied within rea-
sonable ranges. In the absence of data describing inter-cantonal
sexual mixing in Switzerland, we used commuting data and
explored three different scenarios. The two scenarios that assumed
partial sexual mixing between cantons – proportional sexual mix-
ing and mobility-informed mixing – gave rise to a similar pattern,
strengthening the validity of our findings.
Our study has a number of limitations that need be considered
when interpreting the findings. First, we used a relatively simple
compartmental model to describe the transmission of HPV-16,
not taking into account potential sex-specific differences in sexual
behavior and the natural history of infection. Even though we
accounted for heterogeneity in sexual behavior with two different
sexual activity groups, the compartmental structure of the model
implicitly assumes homogeneous mixing within these sub-
groups, i.e., we do not account for specific sexual networks. Fur-
ther, we did not consider different age classes and assumed that
women can only become vaccinated before the age of 18. We also
assumed a closed population without a possible influx or efflux of
virus from or to younger and older age groups. These simplifying
assumptions could affect our model-based estimate of HPV-16
prevalence. Owing to our focus on the transmission and prevalence
of HPV-16, we did not include other high risk HPV types, as some
modeling studies have done [9,30,10,31]. Our results depend on
the assumption that sexual behavior and the subsequent risk of
HPV infection are the same across different cantons. Second, com-
parison of HPV-16 prevalence and the sexual behavior data (i.e.,
the estimated heterosexual partner change rates) between Swiss
and British women needs to be treated with caution. Although
the particular question about the number of new heterosexual
partners was the same in both surveys, the methods for sampling
and data collection differed considerably. While the Swiss SIR sur-
vey interviewed participants by phone, the British National Survey
of Sexual Attitudes and Lifestyles (Natsal-3) relied on individuals
completing questionnaires at the participants’ homes. This differ-
ence could have introduced a social desirability bias that could
result in an underestimation of heterosexual partner changes in
the SIR study. This underestimation might be further compounded
by the fact that the SIR survey included only women. Given the
sensitivity of our model with regard to per partnership transmis-
sion probabilities (Supplementary Material Fig. S5) and heterosex-
ual partner change rates, our calculations of R0 and the
corresponding vaccination thresholds should be interpreted care-
fully. Third, in absence of data about the levels of sexual mixing
between cantons, we assumed that inter-cantonal sexual mixing
is proportional to the observed commuting patterns. We also
assumed that the national average of sexual contacts that are made
with individuals from the same canton is 80%, and that 20% are
made with individuals from another canton. This assumption
was informed by a 1981 Canadian study on couple composition
regarding language (French, English or other) [36]. On average,
18.2% of couples in Quebec were exogamous, with some hetero-
geneity over different regions. Fourth, besides inter-cantonal vari-
ation in HPV vaccination uptake, there is also intra-cantonal
variation. For example, vaccination uptake in Geneva, which has
7320 M. Riesen et al. / Vaccine 35 (2017) 7312–7321a school-based vaccination program, varies significantly according
to nationality and socio-economic status [37]. Investigating the
causes and consequences of intra-cantonal variation in HPV vacci-
nation uptake in Switzerland is part of ongoing work.
There are currently no population-based prevalence estimates
of type-specific HPV in Switzerland. Our modeled pre-vaccination
prevalence of HPV-16 is 3.34%, and is within a plausible range for
women in European countries [23]. A meta-analysis of more than
1 million women estimated HPV-16 prevalence at 4.8% and 3.2%
in Europe and globally, respectively [23]. Only a few studies pro-
vide estimates for the basic reproduction number, R0, or equiva-
lently, the vaccination threshold of HPV-16 or other HPV types.
Ribassin-Majed et al. [38] estimated R0 ¼ 1:73 for HPV-16/18 in
France, corresponding to a vaccination threshold of 67% for one
sex. These values are higher than we calculated for Switzerland,
but lie in a similar range to those expected in Britain (Supplemen-
tary Material Table S3). The lower values that we calculated for
Switzerland underline the possibility of underreporting in the
Swiss sexual behavior survey.
Our results need to be interpreted in the context of the litera-
ture considering heterogeneity in HPV vaccination. The finding
that decreasing heterogeneity in vaccination uptake increases
impact helps to interpret the result by Durham et al. [18] who
showed that vaccination efforts should be targeted towards low-
vaccination states in the USA. Increasing vaccination uptake in
populations with low-vaccination uptake has the strongest effect
for reducing vaccination heterogeneity overall. The study by Shafer
et al. [19] on unequal HPV vaccination uptake among different eth-
nic groups in Canada, suggests that heterogeneous vaccination can
lead to cross-over effects across groups and depends on the
amount of sexual mixing between the groups. Our study supports
these findings and illustrates the effect of heterogeneous vaccina-
tion uptake between different populations and its relationship
with different amounts of sexual mixing between them.
While reducing cantonal variation in vaccination uptake would
help further reduce HPV-16 prevalence in Switzerland, the
expected additional effect would be small. This finding occurred
despite vaccination uptake below the model-based estimate of
vaccination threshold (47.7%) in ten cantons (ZG, AR, SZ, OW, AI,
TG, BE, TI, SH and UR). Assuming homogeneous vaccination at
the same overall level, all cantons would have a vaccination cover-
age of 52% (national average) and would therefore be above the
threshold. One might intuitively expect that the effects of herd
immunity in the latter scenario would result in a substantially
lower prevalence of HPV-16 compared with heterogenous uptake,
which was not the case in our model simulations. One explanation
for this observation is that we compared the short-term effects of
vaccination after 15 years, when prevalence was still declining
rapidly in all cantons and the effects of herd immunity are not fully
active.
Our findings could have implications for the future planning of
HPV vaccination programs at the cantonal and national level in
Switzerland. From the point of view of a particular canton, the
achieved reduction in HPV-16 prevalence will not only depend
on the cantonal vaccination program, but also on the indirect
effects of vaccination efforts in other (particularly neighboring)
cantons and how these effects are dissipated via intra-cantonal
sexual mixing. For the most plausible scenario for inter-cantonal
mixing (mobility-informed sexual mixing), we found that cantons
with high vaccination coverage experience a less effective reduc-
tion in HPV-16 prevalence to what would be expected if they were
isolated (assortative sexual mixing). This effect benefits cantons
with a low vaccination uptake that achieve a higher reduction in
prevalence than expected in the absence of intra-cantonal sexual
mixing. The intensity of cantonal dissipation of vaccination efforts
is again mediated by intra-cantonal sexual mixing. The number ofcantons that surpass a pre-defined relative risk reduction is highly
sensitive to the level of assortative mixing between cantons
(Fig. 5). The results of this study suggest that a harmonization of
programs between cantons, and a reduction in vaccination hetero-
geneity, would result in a stronger effect of vaccination on reduc-
ing HPV-16 prevalence in Switzerland. The generalizability of our
results on the effects of spatial heterogeneity in vaccination uptake
could also be of relevance for the planning of prevention strategies
for other STIs that exhibit similar transmission dynamics. Increas-
ing HPV vaccination uptake in males would help reducing overall
vaccine targeted HPV infection levels, but more modeling studies
are needed to estimate the impact of male uptake by both sex
and geography [15,39,17].
In summary, we found that spatial heterogeneity in HPV vacci-
nation uptake is expected to diminish the effect of vaccination on
HPV-16 prevalence, but the overall effect is small. In Switzerland,
although the expected impact on national prevalence would be rel-
atively small, harmonization of cantonal vaccination programs
would reduce inter-cantonal differences in HPV-16 prevalence.Conflict of Interest
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